. 2019 Jul 1;8(10):4892–4905. doi: 10.1002/cam4.2367

Table 7.

Stratified analyses between CYP24A1 rs2762934 polymorphism and lung cancer susceptibility

Variable	CYP24A1 rs2762934 Adjusted OR (95%CI) P ^a Study Power
Variable	AA	AG		GG (AA/AG) vs GG			AA vs (AG/GG)	AA vs GG
Sex
Male	0.77 (0.20‐2.89) 0.693	0.68 (0.46‐0.99) 0.046^*	0.919	1.00	0.68 (0.47‐0.99) 0.044^*	0.932	0.82 (0.22‐3.08) 0.766	0.72 (0.51‐1.01) 0.057
Female	4.73 (0.54‐41.3) 0.160	0.84 (0.42‐1.68) 0.630		1.00	1.02 (0.54‐1.96) 0.942		4.86 (0.56‐42.33) 0.153	1.18 (0.68‐2.03) 0.560
TNM Stage
I‐II	0.58 (0.07‐4.90) 0.615	0.72 (0.42‐1.23) 0.228		1.00	0.71 (0.42‐1.20) 0.202		0.61 (0.07‐5.18) 0.651	0.73 (0.44‐1.19) 0.200
III‐IV	1.29 (0.36‐4.62) 0.698	0.68 (0.44‐1.04) 0.074		1.00	0.71 (0.47‐1.07) 0.106		1.37 (0.38‐4.92) 0.626	0.78 (0.54‐1.13) 0.184
Lymph node status
Positive	1.23 (0.30‐4.98) 0.775	0.69 (0.43‐1.10) 0.117		1.00	0.72 (0.46‐1.13) 0.151		1.31 (0.32‐5.29) 0.709	0.78 (0.52‐1.17) 0.229
Negative	0.59 (0.07‐5.01) 0.626	0.70 (0.40‐1.22) 0.208		1.00	0.69 (0.40‐1.19) 0.185		0.62 (0.07‐5.31) 0.665	0.71 (0.43‐1.18) 0.187
Type of cancer
SCC	0.95 (0.18‐4.88) 0.947	0.73 (0.45‐1.18) 0.200		1.00	0.74 (0.46‐1.19) 0.211		1.00 (0.19‐5.14) 0.999	0.78 (0.50‐1.20) 0.253
AC	1.88 (0.51‐6.86) 0.342	0.74 (0.45‐1.21) 0.230		1.00	0.81 (0.50‐1.29) 0.375		1.97 (0.54‐7.21) 0.304	0.90 (0.59‐1.36) 0.619
SCLC	0.83 (0.10‐7.02) 0.863	0.54 (0.28‐1.06) 0.073		1.00	0.56 (0.29‐1.06) 0.077		0.91 (0.11‐7.70) 0.930	0.61 (0.33‐1.10) 0.100

^* P ≤ 0.05 value indicates statistical significance; P ^a adjusted for age and sex.

Bold indicates the siginificant value P ≤ 0.05 and the value of study power>0.8

Abbreviations: AC, adenocarcinoma; CI, confidence interval; ORs, odds ratios; SCC, Squamous cell carcinoma; SCLC, small cell lung cancer; TNM, tumor‐lymph node‐metastasis.